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Abstract
Mathematical models are often created to analyze the complicated behavior of many
physical systems. One such system is that of the interaction between cancer cells, the im-
mune system, and various treatments such as chemotherapy, radiation, and immunotherapy.
Using models that depict these relationships gives researchers insight on the dynamics of this
complicated system and possibly ideas for improved treatment schedules.
The model presented here gives the relationship of cancer cells in different phases of de-
velopment, along with immune cells and cycle-specific chemotherapy treatment. This model
includes a constant delay term in the mitotic phase, where cells divide, which leads to more
complicated analyses. Optimal control theory is used to minimize the cost of the chemother-
apy and the number of cancer cells. Numerical methods, such as a forward-backward sweep
method and adjusted methods to evaluate delays, are used to show qualitative treatment
options.
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1Chapter 1
Introduction
Cancer is a term used to describe over 100 diseases in which cells are changed in negative
ways. These cells typically develop in three major phases: the mitotic (dividing) phase,
the quiescent (resting) phase, and the interphase (cell growth). The body’s natural defense
against these cells are the white blood cells, or lymphocytes. However, when the cancer cells
overpower the lymphocytes, it is common for the cells to be treated with chemotherapy. Liu
et al. [19] consider this system of interactions between the cancer cells, lymphocytes, and
chemotherapy extensively.
Using chemotherapy as a treatment option presents a serious drawback. While this treat-
ment will kill the cancer cells, it will also kill the lymphocytes and presents a toxicity concern
to the patient. This complexity brings about varying strategies of treatment. Immunotherapy
is one such treatment, which could increase the patient’s success with combating cancer by
boosting the immune system while other treatments are applied. Research from Barsoumian
et al. [1] investigate stimulating immune system cells at checkpoints before cancer cells are
detected to combat cancer before it becomes malignant. Kirschner and Panetta [17] inves-
tigated a treatment combining chemo- and immunotherapies, but found that their specific
treatment is better suited as a monotherapy or with other immune components.
2Mathematical approaches are often sought out to preface clinical trials, as different sce-
narios can be considered without consequence. This allows for a more accurate approach to
treatments and a better quality of life for patients [21]. Several mathematical researchers
have taken on this project in different ways. Optimal control theory is often applied to can-
cer treament by creating a means of quantifying the most desired, or “best,” behavior of
the tumor and immune system dynamics. In the case of cancer treatment, “best” usually
means minimizing the number of cancer cells while minimizing the toxicity and damage done
to the body caused by chemotherapy. Fister and Donnelly [10] extended the Kirschner and
Panetta work using optimal control theory to define and analyze a “best” solution concept.
de Pillis et al. [7] analyzed optimal control strategies with traditional nonlinear controls in the
objective functionals for the case of chemo-immunotherapeutic treatments. Works by Kim
et al. [16], Swan and Vincent [24], and Murray [22] are examples of successfully applying
this concept as well. In this thesis, we analyze two situations of “best,” which are given by
the objective functionals. The first minimizes cancer cell count and the cost associated with
chemotherapy throughout the entire process, while the second seeks to minimize the cost of
the chemotherapy throughout, as well as the cancer cell count at the final time.
Other researchers utilize delays to model the interaction between the tumor cells and the
immune system. The recent work by Cui and Xu [5] studies delay terms in the phase shift
from the mitotic phase to the production of the daughter cells in models that investigate
nonnecrotic and necrotic tumors. The aforementioned study by Liu et al. [19] delves deeply
into a cycle-specific model, and considers the presence of a delay between the interphase and
mitotic phase. Their work shows that the delay greatly influences the cancer as a whole
when considering treatment. Delays in differential equations present a unique challenge to
analysis, as shown in [2]. Challenges become more difficult to accommodate when the delay
is time– or state–dependent. The case for Liu et al. [19] considers a constant delay. Here, we
investigate the nondimensionalized model from [19], attempting to find an optimal treatment
3schedule while incorporating the importance of the delay.
Collins et al. [3] provides the existence and uniqueness of a solution for the delay dif-
ferential equation system and the existence of an optimal control. From there, this paper
seeks to approximate solutions for a treatment schedule, differing from [19] in that we seek
to incorporate both the delay and the optimal control.
The arrangement of this thesis begins with a description of the model being used in
Chapter 2, with Chapter 3 giving context to the objective functionals and the characterization
of an optimal control. Numerical methods, such as Runge-Kutta and forward-backward sweep
methods, are located in Chapter 4. A discussion of results is provided in Chapter 5, which
presents different cases of a “best” situation and a scheduled treatment approach to better
model real life. We conclude with Chapter 6, summarizing results and exploring possibilities
for future work.
4Chapter 2
The Model
Several models in the literature analyze the effects of chemotherapy on patients. Most fo-
cus on minimizing both the amount of chemotherapy administrated and the final size of
the tumor. Some researchers model different aspects of the immune system, while oth-
ers investigate an immunotherapeutic approach [17]. Newer models propose a combined
immuno–chemotherapy treatment, or focus on the different cell phases, as in [25] and [19].
Optimal control theory is often applied to cancer therapy models. The works of Swan
and Vincent [24] and Murray [22] use optimal control theory to minimize the toxicty of
chemotherapy. Other research by de Pillis et al. [7] and Fister and Donnelly [10] utilize
optimal control theory to find an effective treatment schedule.
2.1 The Model
This model considers the effect of including different phase shifts of the tumor cells. There are
three phases of the cell cycle: the mitotic phase where cells divide, the quiescent phase where
cells rest, and the interphase when cells prepare for mitosis. Liu et al. [19] developed the
relationships between the cells in the three phases, the immune system, and the cycle-specific
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drug. Table 2.1 gives a description of each variable.
Variable Variable Description
x number of cancer cells in interphase phase
y number of cancer cells in the mitotic phase
z number of cancer cells in the quiescent phase
I number of lymphocytes
u biomass of chemotherapy drug in mg
Table 2.1: Description of Variables
2.1.1 Existence and Uniqueness
Existence and uniqueness of a solution for this delay differential equation system was es-
tablished using results from Driver [9] and can be found in Collins et al. [3]. The control
term, v(t), represents the inclusion of chemotherapy as a drug administration, placing it
appropriately in the differential equation that quantifies the amount of drug in the system.
2.1.2 The Equations
The system of differential equations is given by:
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dx
dt
= sα3z(t)− α1x(t)− (σ1 + k1I(t))x(t) (2.1.1)
dy
dt
= α1x(t− τ)− (α2 + σ2 + k2I(t)y(t)− k4(1− e−k5u(t))y(t) (2.1.2)
dz
dt
= 2s−1α2y(t)− (α3 + σ3 + k3I(t))z(t) (2.1.3)
dI
dt
= k +
(
ρI(t)(x+ y + sz)n
a+ (x+ y + sz)n
)
− (σ4 + c1x(t) + c2y(t) + c3z(t))I(t)
− k6(1− e−k7u(t))I(t) (2.1.4)
du
dt
= −γu(t) + v(t) (2.1.5)
where the initial conditions are
x(t) = φ(t), t ∈ [−τ, 0], y(0) = y0, z(0) = z0, I(0) = I0, u(0) = u0.
Here, all constants are positive and the interphase is the only phase with a delay present.
We note that Liu et al. [19] present two versions of this model, one of which is nondimension-
alized. For this thesis, we analyze the nondimensionalized model. Note that the nondimen-
sionalization process introduces a parameter s, which represents the number of inital cancer
cells in the resting phase per number of initial cells in the interphase, as shown above. Table
2.2 provides a brief description of the parameters, while Table 2.3 gives the allowable range
and specific values used for the parameters taken from Liu et al. [19].
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2.1.3 Equation Descriptions
In general, positive terms indicate a contribution of cells to a population and negative
terms indicate a decrease in the number of cells from a population. Each state equation
includes growth and natural death terms, and certain parameters exist to represent how the
chemotherapy is killing cells in the system.
The Tumor Equations
The αi terms, for i = 1, 2, 3, are transition terms from one tumor phase to another, while
the σi terms, for i = 1, 2, 3, are natural death terms for their respective phases. The destruc-
tion caused by drugs to the mitotic cancer cell population is given by (1− e−k5u(t)), as seen
in [8]. The chemotherapy in use is cycle-specific, so the mitotic phase is the only one affected
directly.
The Lymphocyte Equation
The nonlinear growth term,
ρI(t)(x+ y + sz)n
a+ (x+ y + sz)n
, was chosen by Villasana and Radun-
skaya [25] to represent the immune cell dynamics. They chose a Michaelis–Menten term to
represent the stimulation of the immune cells by the presence of cancer cells, but also to
indicate that the immune cells may reach a saturation point. This form reflects that this
term should be zero in the case of no cancer cells, but approaches the horizontal asymptote
as the lymphocytes reach a saturation level. The destruction of the lymphocyte populations
caused by the chemotherapy drug is given by the term (1− e−k7u(t)), [8].
Chemotherapy Drug Equation
The first term, −γu, represents the natural decay of the drug in the bloodstream. The
addition of the control term v(t) will represent a direct application of the drug. The ex-
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ponential kill terms due to the detrimental effects of chemotherapy are incorporated into
the mitotic phase equation, as the chemotherapy is cycle–specific, and into immune system
equation, as the chemotherapy drug destroys both tumor and healthy cells indiscriminately.
Parameter Description
α1 rate at which cells move into mitosis
α2 rate at which cells move into the resting phase
α3 rate at which cells leave resting and enter cell cycle
ci for i = 1, 2, 3 binding losses with immune cells
σi for i = 1, 2, 3, 4 natural death proportions for x, y, z, and I
ρ proportional growth of I due to interaction with cancer cells
n fractional exponent of growth from stimulus of cancer cells
a rate at which I reaches saturation without stimulus
k growth rate of I with no cancer cells
ki for i = 1, 2, 3 rate at which I destroys cells in different phases
k4, k6 proportion of removal of y and I
k5, k7 proportion of drugs in removal of y and I
γ natural decay rate of chemotherapy
τ time of cells in interphase (delay variable)
Table 2.2: Parameter Descriptions
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Parameter Allowable Range [19] Value Used
α1 0− 1/day 1
α2 0− 1/day 0.6
α3 0− 1/day 0.9
c1 0.01× 10−6 − 1× 10−6/cell day 0.2× 10−6
c2 0.01× 10−6 − 1× 10−6/cell day 0.8× 10−6
c3 0.01× 10−6 − 1× 10−6/cell day 0.108× 10−6
σ1 0− 1/day 0.11
σ2 0− 1/day 0.28
σ3 0− 1/day 0.1× 10−4
σ4 0− 1/day 0.3
ρ 0.2/day 0.2
a 0.5× (0.1× 106 cells)3 0.5× (0.1× 106)3
k 0.15× 106 cell/day 0.15× 106
k1 0.1× 10−8 − 1× 10−8 /cell day 0.1× 10−7
k2 0.1× 10−8 − 1× 10−8 /cell day 0.4× 10−8
k3 0.1× 10−8 − 1× 10−8 /cell day 0.1× 10−8
k4 0− 1/day 0.25
k5 0.01× 10−2 − 1× 10−2 /mg 1× 10−2
k6 0− 1/day 0.3× 10−1
k7 0.01× 10−2 − 1× 10−2 /mg 0.5× 10−2
γ 0.1× 10−2 − 1× 10−2 /day 0.3× 10−2
Table 2.3: Parameter Ranges and Values
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Chapter 3
Optimal Control
Optimal control theory evolved from an older branch of mathematics called calculus of vari-
ations. Different problems in this field, such as the brachistochrone and the Bolza problems,
eventually developed the techniques that we call optimal control theory today. A typical
problem starts with a system of differential equations modeling a physical process. We then
wish to find a control belonging to some admissible control set that causes the system to
follow an ideal pattern. We quantify “ideal” by the objective functional, and seek to find the
control that minimizes or maximizes said objective functional.
In this chapter, we extend Pontryagin’s Minimum Principle as taken from Kamien and
Schwartz [14] to analyze the optimal control problem with an incorporated delay. We consider
two objective functionals to quantify a “best” scenario, implementing a quadratic control to
make the analysis more straightforward. A future analysis might include examining a linear
control, but for the purposes of this study we limit ourselves to the quadratic case. We then
define the respective Hamiltonians to obtain a characterization of the control. From the
Hamiltonians, a system of initial state equations coupled with the adjoint equations result
to be used in the numerical approximations to update the control.
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3.1 Objective Functionals
We seek to minimize both objective functionals. The first is given by
J1(v) =
∫ tf
0
[ 
2
v2(t) + x(t) + y(t) + sz(t)
]
dt (3.1.1)
over the set V = {t ∈ [0, tf ]|0 ≤ v(t) ≤ 1}, where x, y, and z are the cancer cells in their
respective cycles and  is a weight parameter that allows us to emphasize the cost of the
chemotherapy drug to the system. Here, we wish to minimize the cost of the chemotherapy
and the cell counts throughout the entire time frame.
We also wish to minimize a second objective functional
J2(v) =
∫ tf
0

2
v2(t)dt+ [x(tf ) + y(tf ) + sz(tf )] (3.1.2)
over the same set V with the same weight factor . Here, we minimize the cost associated
with the drug throughout, but only minimize the cancer cells x, y, and z at the final time.
3.1.1 Existence
Existence of an optimal control in the case of the second objective functional (3.1.2) is given
in [3], using a theorem from Das and Sharma [6]. Existence for the first objective functional
(3.1.1) is shown by a similar argument.
3.1.2 Characterization of the Optimal Control
With the existence of an optimal control, we may obtain the analytic representation of the
control for the objective functionals. In a standard optimal control setting, the form of
the adjoint equations and the transversailty conditions follows from Pontryagin’s Minimum
Principle [14]. However, the presence of the delay necessitates modifications to this standard
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approach. An analysis presented in [14] shows that the presence of the delay adds terms
to the necessary conditions obtained in the nondelay case. We note that since the deviated
argument does not appear in the control, the necessary conditions for optimality reduce to
those in the standard case. The adjoint equations, on the other hand, will include additional
terms as the deviated argument does appear in the state equations. We note that the analysis
presented in Kamien and Schwartz [14] covers only the case of constant delay. More general
cases are covered in [15], [13], [12], [4], [11].
The first step is to form the Hamiltonian, which relates the integrand of the objective
functional to the state equations using adjoint variables λi, i = 1, ..., 5. Since the control
is bounded we construct the Lagrangian, which combines the Hamiltonian and the optimal
control with penalty multipliers. Taking partial derivatives of the Lagrangian with respect
to each of the state variables will lead us to the representation of the optimal control. We
emphasize that the partial derivative with respect to the terms involving the state variable,
x, will have two forms, as the presence of the delay adds terms to the necessary conditions
that would vanish in the case of no delay [14].
Theorem 3.1.1 (Characterization of the Optimal Control for Objective Functional 3.1.1).
Given an optimal control, v∗(t), and solutions to the corresponding state system, there exist
3.1. Objective Functionals 13
adjoint variables λi for i = 1, 2, ..., 5 satisfying the following:
−∂L
∂x
− ∂L
∂x(t− τ)
∣∣∣
t+τ
= λ
′
1 = −1 + λ1(α1 + σ1) + λ1k1I − λ4
(
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c1I − λ2α2|t+τ ,
for 0 ≤ t < tf − τ
− ∂L
∂xt
= λ
′
1 = −1 + λ1(α1 + σ1) + λ1k1I − λ4
(
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c1I,
for tf − τ ≤ t ≤ tf .
For the last four adjoints, the interval for t is [0, tf ], and we have
−∂L
∂y
= λ
′
2 = −1 + λ1(α1 + σ1) + λ2k2I + λ2k2I + λ2k4(1− e−k5u(t))
+ λ2(α2 + σ2)− λ3(2s−1α2)− λ4
((
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
− c2I
)
−∂L
∂z
= λ
′
3 = −s− λ1sα3 + λ3(α3 + σ3 + I(t)k3)
− λ4
(
ρaI(t)nas(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c3I(t)
−∂L
∂I
= λ
′
4 = λ1k1x+ λ2k2y + λ3k3z
− λ4
(
ρ(x+ y + sz)n
a+ (x+ y + sz)n
+ σ4 + c1x+ c2y + c3z + k6(1− e−k7u)
)
−∂L
∂u
= λ
′
5 = λ2k4k5e
−k5u(t)y + λ4k6k7e−k7u(t)I + λ5γ
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where λi(tf ) = 0 for i = 1, 2, ..., 5. Furthermore, v
∗(t) can be represented by
v∗(t) = min
(
max
(
0,
−λ5(t)

)
, 1
)
.
Proof. We begin by forming the Lagrangian. Since 0 ≤ v(t) ≤ 1, the controls are bounded;
thus, the Lagrangian takes the following form:
L = H1 −W1(t)v(t)−W2(t)(1− v(t))
where H1 is the Hamiltonian given by
H1 = x(t) + y(t) + sz(t) +

2
v2(t)
+ λ1[−(α1 + σ1)x(t) + sα3z(t)− k1x(t)I(t)]
+ λ2[α1x(t− τ)− (α2 + σ2)y(t)− k2y(t)I(t)− k4(1− e−k5u(t))y(t)]
+ λ3[2s
−1α2y(t)− (α3 + σ3)z(t)− k3z(t)I(t)]
+ λ4[k +
ρI(t)(x+ y + sz)n
(a+ (x+ y + sz)n)
− (σ4 + c1x(t) + c2y(t) + c3z(t))I(t)− k6(1− e−k7u(t))I(t)]
+ λ5[−γu(t) + v(t)]
and Wi(t) ≥ 0, for i = 1, 2, are penalty multipliers such that
W1(t)v(t) = 0
W2(t)(1− v(t)) = 0
 at v∗(t). (3.1.3)
Here, the penalty terms are subtracted from the Hamiltonian, as we are solving a mini-
mization problem. To find the representation for v∗(t), we analyze the necessary condition
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for optimality. From Kamien and Schwartz [14], we see that the optimality conditions are
∂L
∂v(t)
+
∂L
∂v(t− τ) = 0, for 0 ≤ t < tf − τ
∂L
∂v(t)
= 0, for tf − τ ≤ t ≤ tf .
However, since the delay does not appear as an argument in the control, the above
conditions reduce to
∂L
∂v(t)
= 0 (for t0 ≤ t ≤ tf ). We then have
∂L
∂v
=
∂H
∂v
−W1 +W2 = 0
⇒ v + λ5 −W1 +W2 = 0.
To determine an explicit expression for v, consider three cases:
1. Suppose 0 < v(t) < 1. Then W1 = W2 = 0, so
v =
−λ5

.
2. Suppose v(t) = 1. Then W1 = 0, so
v +
W2

=
−λ5

≥ 1.
3. Suppose v(t) = 0. Then W2 = 0, so
v − W1

=
−λ5

≤ 0.
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Combining these cases gives the characterization for the optimal control v∗(t) as
v∗(t) = min
(
max
(
0,
−λ5(t)

)
, 1
)
. (3.1.4)
In a similar manner, we obtain the analytic representation for the control for the second
objective functional.
Theorem 3.1.2 (Characterization of the Optimal Control for Objective Functional 3.1.2).
Given an optimal control, v(t), and solutions to the corresponding state system, there exist
adjoint variables λi for i = 1, 2, ..., 5 satisfying the following:
−∂L
∂x
− ∂L
∂x(t− τ)
∣∣∣
t+τ
= λ
′
1 = λ1(α1 + σ1) + λ1k1I − λ4
(
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c1I − λ2α2|t+τ ,
for 0 ≤ t < tf − τ
− ∂L
∂xt
= λ
′
1 = λ1(α1 + σ1) + λ1k1I − λ4
(
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c1I,
for tf − τ ≤ t ≤ tf
For the last four adjoints, the interval for t is [0, tf ], and we have
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−∂L
∂y
= λ
′
2 = λ1(α1 + σ1) + λ2k2I + λ2k2I + λ2k4(1− e−k5u(t))
+ λ2(α2 + σ2)− λ3(2s−1α2)− λ4
((
ρaIn(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
− c2I
)
−∂L
∂z
= λ
′
3 = s− λ1sα3 + λ3(α3 + σ3 + I(t)k3)
− λ4
(
ρaI(t)nas(x+ y + sz)(n−1)
(a+ (x+ y + sz)n)2
)
+ λ4c3I(t)
−∂L
∂I
= λ
′
4 = λ1k1x+ λ2k2y + λ3k3z
− λ4
(
ρ(x+ y + sz)n
a+ (x+ y + sz)n
+ σ4 + c1x+ c2y + c3z + k6(1− e−k7u)
)
−∂L
∂u
= λ
′
5 = λ2k4k5e
−k5u(t)y + λ4k6k7e−k7u(t)I + λ5γ
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where λi(tf ) = 1 for i = 1, 2, λ3(tf ) = s, and λi(tf ) = 0 for i = 4, 5. Again, v
∗(t) can be
represented by
v∗(t) = min
(
max
(
0,
−λ5(t)

)
, 1
)
. (3.1.5)
Proof. We note that the transversality conditions take a different form due to the presence of
the salvage terms in the objective functional. The form of these conditions is taken from [14].
As before, we begin by forming the Lagrangian. Since 0 ≤ v(t) ≤ 1, the controls are bounded;
thus, the Lagrangian takes the following form:
L = H2 −W1(t)v(t)−W2(t)(1− v(t))
where H2 is the Hamiltonian given by
H2 =

2
v2(t)
+ λ1[−(α1 + σ1)x(t) + sα3z(t)− k1x(t)I(t)]
+ λ2[α1x(t− τ)− (α2 + σ2)y(t)− k2y(t)I(t)− k4(1− e−k5u(t))y(t)]
+ λ3[2s
−1α2y(t)− (α3 + σ3)z(t)− k3z(t)I(t)]
+ λ4[k +
ρI(t)(x+ y + sz)n
(a+ (x+ y + sz)n)
− (σ4 + c1x(t) + c2y(t) + c3z(t))I(t)− k6(1− e−k7u(t))I(t)]
+ λ5[−γu(t) + v(t)]
and Wi(t) ≥ 0, for i = 1, 2, are penalty multipliers such that
W1(t)v(t) = 0
W2(t)(1− v(t)) = 0
 at v∗(t) (3.1.6)
Again, the penalty terms are subtracted from the Hamiltonian, as we are solving a min-
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imization problem. To find the representation for v∗(t), we analyze the necessary condition
for optimality. From Kamien and Schwartz [14], we see that the optimality conditions are
∂L
∂v(t)
+
∂L
∂v(t− τ) = 0, for 0 ≤ t < tf − τ
∂L
∂v(t)
= 0, for tf − τ ≤ t ≤ tf .
However, since the delay does not appear as an argument in the control, the above
conditions reduce to
∂L
∂v(t)
= 0 (for t0 ≤ t ≤ tf ). We then have
∂L
∂v
=
∂H
∂v
−W1 +W2 = 0
⇒ v + λ5 −W1 +W2 = 0.
To determine an explicit expression for v, consider three cases:
1. Suppose 0 < v(t) < 1. Then W1 = W2 = 0, so
v =
−λ5

.
2. Suppose v(t) = 1. Then W1 = 0, so
v +
W2

=
−λ5

≥ 1.
3. Suppose v(t) = 0. Then W2 = 0, so
v − W1

=
−λ5

≤ 0.
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Combining these cases gives the characterization for the optimal control v∗(t) as
v∗(t) = min
(
max
(
0,
−λ5(t)

)
, 1
)
. (3.1.7)
By comparing (3.1.4) and (3.1.5), we see that our representations for the quadratic con-
trols are the same for these cases regardless of the choice of objective functionals (3.1.1) and
(3.1.2). Future work could include the investigation of a linear control term.
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Chapter 4
Numerical Methods
In a typical delay differential equation (DDE) setting, MATLAB offers a built-in solver called
dde23 [23]. This would accommodate the delay nicely, considering our case of a constant
delay. However, the implementation of the control in the model makes dde23 incredibly
difficult to edit for our purposes. We therefore construct our own solver, which incorporates
a modified Runge-Kutta method, and utilize the forward-backward sweep method provided
by Lenhart and Workman [18] to update the control and obtain analytical representations of
the system.
4.1 Forward–Backward Sweep Method
We take our approach for numerical solutions from Lenhart and Workman [18], using RK4 as
the initial value problem solver. We solve the state system forward in time using the initial
conditions, then the adjoint system backward in time using the transversality conditions.
Each iteration of the sweeps updates the control and checks convergence. There are several
stopping criteria for this method, including observing the averages of previous and current
iterations. However, we choose to stop the sweeps when the difference between the values
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of the control before and after the sweep are negligable. If this were the case, the control is
stored using its analytical representation. Otherwise, the process repeats.
4.2 The Delay
The delay in the model represents the lag between shifting from the interphase to the division
phase for the cancer cells and is an important distinction from the model presented by
Villasana and Radunskaya [25]. Liu et al. [19] argue that the quiescent phase is the most
important compartment for cancer treatment, as studies have shown that these cells can avoid
the chemotherapy. Thus, inclusion of this delay presents an insightful aspect for treatment.
Due to this presence, accommodations must be made for the analysis.
Several cases for the delay could have been chosen, but our case incorporates a constant
delay, τ . A standard implementation of RK4 does not account for the delay, leading to an
adjusted time mesh for the analysis. Here, this means that the deviated argument (t − τ)
found in Equation (2.1.2) will store the information from the appropriate lagged time step,
and that this lag will have the same size throughout the process. A visual representation of
the difficulty posed by the presence of the delay is shown in Figure 4.2.1. Storing previous
information only holds when the lag has passed a threshold where the lag (t− τ) would hit
t1 going forward, or (tf − τ) would hit (tf−1) going backward. Before this threshold, we have
an initial function that extends behind the inital time, [2]. In our case, this initial function
has a constant value equal to the initial condition for x(t) in the forward sweep, and zero or
one for the backward sweep, with respect to the appropriate adjoint system.
These initial functions can cause points of discontinuity when solving the system, as the
right-hand derivative may not equal the left-hand derivative at t0 or tf . Discontinuities such
as these can not only cause issues with the first derivative, but can propogate throughout
future integration intervals [2]. Due to this, these possible points of discontinuity must be
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Figure 4.2.1: Thresholds for delays
included in our time mesh to accommodate the numerical methods. Since our initial functions
are mathematically “nice,” we do not encounter issues of irregularity, which could cause a
loss of uniqueness [2].
In the case of our constant delay, the Runge-Kutta method takes the form
η(tn + θhn+1) = yn + hn+1
∑s
i=1 bi(θ)f(t
i
n+1, Y
i
n+1, η(t
i
n+1 − τ)), 0 ≤ θ ≤ 1, (4.2.1)
Y in+1 = yn + hn+1
∑s
j=1 aijf(t
j
n+1, Y
j
n+1, η(t
j
n+1 − τ)), i = 1, 2, ..., s (4.2.2)
where, for hn+1 ≤ τ , η(tjn+1− τ) is known for any j. Thus, we get the following theorem from
Bellen and Zennaro [2].
Theorem 4.2.1 (Global Order of Delay Differential Equation Method [2]). Consider the
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Delay Differential Equation (DDE) with a constant delay
 y
′(t) = f(t, y(t), y(t− τ)), t0 ≤ t ≤ tf ,
y(t) = φ(t), t ≤ t0,
(4.2.3)
where f(t, y, x) is Cp–continuous in [t0, tf ] × Rd × Rd and the initial function φ(t) is Cp–
continuous. Moreover, assume that the mesh ∆ = {t0, t1, ..., tn, ..., tN = tf} includes the
discontinuity points ξi = iτ , i = 1, ..., p, lying in [t0, tf ] and that the underlying continuous
Runge-Kutta (CRK) method has discrete order p and uniform order q. Then the DDE method
for (4.2.1), (4.2.2) has discrete global order and uniform global order q′ = min{p, q+ 1}; that
is
max
1≤n≤N
||y(tn)− yn|| = O(hq′)
and
max
t0≤t≤tf
||y(t)− η(t)|| = O(hq′),
where h = max1≤n≤Nhn.
Since the algorithm proceeds with constant stepsize h = τ/m for some integer m ≥ 1,
the deviated arguments take the values
tjn+1 − τ = tjn+1−m = tn−m + cjh, j = 1, ..., s.
Also, since the CRK method is natural, η(tjn+1) = Y
j
n+1 and η(t
j
n+1− τ) = Y jn+1−m. Thus,
we get the simplified method
yn+1 = yn + h
∑s
i=1 bif(t
i
n+1, Y
i
n+1, Y
i
n+1−m) (4.2.4)
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Y in+1 = yn + h
∑s
j=1 aijf(t
j
n+1, Y
j
n+1, Y
j
n+1−m), i = 1, 2, ..., s. (4.2.5)
This theorem outlines the method we implement for our specific delay case. The con-
tinuous RK method uses interpolants to connect discrete values of the solution. In other
words, the RK method makes distinct approximations for each time step, and then inter-
polates between approximations to get a continuous RK solution. Additionally, since RK4
is a one–step solver, we get the natural continuous extension automatically, as defined in
Appendix A. With these methods in place, we may analyze our model, using the modified
RK4 as the appropriate solver.
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Chapter 5
Results
Each simulation uses the initial conditions x(0) = y(0) = 0.1 × 106 cells, z(0) = 0.2 × 106
cells, I(0) = 2× 106 cells, and u(0) = 8. We first replicate the results in Liu et al. [19], then
analyze the cases of continuous treatment and two scheduled treatment approaches. The
function trapz in MATLAB is used to obtain the area under the curve for the amount of
treatment administered to compare treatment applications.
Previous Results
Our first goal was to replicate the work done by Liu et al. [19]. This verified that the
implementation created here was consistent with the one used in [19]. Figure 5.0.1 shows the
growth of the tumor with and without initial drug, but does not include the implementation
of the control. We see that our method successfully duplicates the results of Liu et al. [19],
which shows a significant decrease in the number of cancer cells in the treatment schedule
that consists only of an initial dose of the chemotherapy drug.
New Results
We then incorporated the control to determine how it affected the model. Figure 5.0.2
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Figure 5.0.1: Replication of Liu et al. [19] results
shows the results with respect to the first objective functional. We see that the cancer
follows an exponential growth pattern in the case of no drug. With the inital dosage of
chemotherapy, but still no control, the cancer cells are reduced, as we saw from [19], but we
see greater reduction of cells in the case with both the initial drug and the optimal control.
The lymphocytes, shown in Figure 5.0.3, exhibit a bit of growth when more cancer cells
die in the case of initial dose with the control, as the parameters treat the cancer cells as a
larger threat to the lymphocytes than the chemotherapy. The optimal treatment schedule is
shown in Figure 5.0.4, following an almost on/off pattern starting with no drug. Analyses
performed on the second objective functional provided results that were very similar in nature.
28
Figure 5.0.2: Total Number of Cancer Cells for Continuous Treatment
Schedule One: Four Days of Treatment
Next, we examine a more realistic approach to chemotherapy treatment. In this case, a
patient would receive a scheduled drug administration of 4 days of treatment, 26 days of rest,
receive another 4 days of treatment, and rest the last 26 days, shown by Figure 5.0.8. This
schedule gives the body time to rest between treatments, but doesn’t allow the cancer cells
as much time to recover. The two cases considered here were the cases of initial dosage only
and including the optimal control with respect to the first objective functional.
Figure 5.0.5 shows that with the control, the cancer cells drop at the second treatment
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Figure 5.0.3: Total Number of Lymphocytes for Continuous Treatment
iteration, and never fully recover when compared to the initial dose only. The cancer cells
end at 2.5×106 number of cells in the control case and 2.9×106 in the initial dose only case.
Thus, their final cell count decreases by 16.6 percent in the case of control over the case of
initial dose only. In Figure 5.0.6, the lymphocytes pick up slightly after the first round of
treatment is over, and again after the second treatment. We see a fluctuation in the middle
where the lymphocytes start to die off more as more cancer cells grow, but then recover after
the second treatment is administered for a higher final cell count than in the case of the inital
drug only.
The amount of drug in the system over 60 days is given by Figure 5.0.7. In the case
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Figure 5.0.4: Continuous Treatment Schedule
of initial drug only, we administer the allotted dosage at the start time, and the amount
of chemotherapy drug in the system steadily decreases over time. With the control, we
never exceed the amount of drug given by the initial dose only case. At the final time,
the inital dose case has an AUC (area under the curve) of 493.3 mg, while the control case
has a AUC of 293.5 mg. Thus, there is a decrease of 33.2 percent in the total amount of
chemotherapy in the system given by the optimal control case over the amount given by only
the initial dosage. This treatment schedule produced lower cancer cell counts, higher final
lymphocyte counts, and less total drug in the system than in the case of initial dosage only.
This supports the hypothesis that incorporating an optimal control to the model will mini-
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mize the cost associated with chemotherapy while also minimizing the number of cancer cells.
Figure 5.0.5: Total Number of Cancer Cells for Treatment Schedule One
Schedule Two: Two Days of Treatment
We also consider the case of two days of treatment and thirteen days of rest, repeated
four times, with respect to the first objective functional. This treatment schedule is more
plausible than the first, as this allows patients to leave the hospital during the sixty days.
However, we do not see improved results when compared to Schedule One. Figure 5.0.9 shows
that there are decreases in the number of cancer cells when the drug is administered, but
they recover too quickly before the next iteration of treatment. The final cancer cell count
32
Figure 5.0.6: Total Number of Lymphocytes for Treatment Schedule One
actually increases by 20.9 percent in the two day schedule over the initial dose case.
Figure 5.0.10 shows that this treatment schedule does not help the lymphocyte population
when compared to the initial dose case. This is due to the increased number of cancer cells
that survived. The overall amount of chemotherapy in the system, as shown in Figure 5.0.12,
is 56.5 percent less than the initial dose only, with an AUC of 191.2 mg. However, this
amount of treatment does not show improved results for cancer cell count over Schedule
One. These results imply that two days of treatment is not enough to harm the cancer
cells to the point where they never fully recover. The four day treatment seems to be the
experiment that provided the most beneficial outcome in terms of minimizing cancer cell
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Figure 5.0.7: Amount of Drug in the System for Treatment Schedule One
count and the negative effects of chemotherapy.
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Figure 5.0.8: Drug Administration for Treatment Schedule One
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Figure 5.0.9: Total Number of Cancer Cells for Treatment Schedule Two
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Figure 5.0.10: Total Number of Lymphocytes for Treatment Schedule Two
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Figure 5.0.11: Amount of Drug in the System for Treatment Schedule Two
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Figure 5.0.12: Drug Administration for Treatment Schedule Two
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Chapter 6
Discussion
This thesis shows the numerical analysis of the delay differential equation system given by
Liu et al. [19] with the addition of an optimal control. Existence of such a system and control
is established from Collins et al. [3]. Analysis techniques included modifying Pontryagin’s
Minimum Principle [14] for the representation of an optimal control, a forward-backward
sweep method utilizing RK4 as the solver, taken from Lenhart and Workman [18], and
adjusted analyses to incorporate the delay given by Bellen and Zennaro [2].
The numerical simulations indicated that the particular treatments outlined here with
the specified parameters did not kill the cancer cells entirely. However, we do see that the
implementation of the control significantly reduced the number of cells in the system in the
continuous and four–day treatments while also administering less chemotherapy drug in each
case. However, in the case of two–day treatment, the cancer cells were able to rebound,
which had worsened effects for the lymphocytes. Overall, the continuous treatment approach
provided the best results in terms of minimizing cancer cell count throughout the time frame
and at the final times. We note, too, that the experiments for the second objective functional
were very similar to each respective experiment here. Thus, investigating this model with a
delay and a control was insightful for future work.
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Other implementations or delay cases could improve the results we see here. Including
more delays in the cancer system would better model how the cancer behaves, which could
provide more realistic results. The delay could also be a function of the drug, as there exists
a lag between when the drug is administered and when the drug attacks the tumor cells [19].
Other components of the immune system could be incorporated, instead of only one factor.
The immune system as a whole is very complicated and this model does not encompass that
complexity. One interesting direction for future work could involve using optimal control
theory to minimize the time of treatment instead of the drug administration, resulting in a
different objective functional. Instead of optimizing the amount of drug administered, we
could consider optimizing the amount of time when the drug is administered. Investigation
of a control term in the immune system, or control terms in both the immune system and
applied drug, could also provide interesting results.
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Appendix A
Definitions
In this section, we give a precise statement of the definition of a natural continuous extension
of a Runge–Kutta method.
Definition A.0.1 (Natural Continuous Extension [2]). We say that the interpolant η(t) in
η(tn + θhn+1) = yn + hn+1
v∑
i=1
bi(θ)g(t
i
n+1, Y
i
n+1), 0 ≤ θ ≤ 1
of order (and degree) q is a natural continuous extension (NCE) of the RK method
Y in+1 = yn + hn+1
v∑
j=1
aijg(t
i
n+1, Y
i
n+1), i = 1, ..., v, yn+1 = yn + hn+1
v∑
i=1
big(t
i
n+1, Y
i
n+1)
of order p if the polynomials bi(θ), i = 1, ..., v, are such that η(t) satisfies the additional
asymptotic orthogonality condition
∣∣∣∣∣∣ ∫ tn+1
tn
G(t)[z′n+1(t)− η′(t)]dt
∣∣∣∣∣∣ = O(hp+1n+1)
for every sufficiently smooth matrix–valued function G, uniformly with respect to
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n = 1, ..., N − 1, where zn+1(t) is the solution to the local problem z
′
n+1(t) = g(t, zn+1(t)), tn ≤ t ≤ tn+1,
zn+1(tn) = y
∗
n.
We note that for any one–step collocation method, the collocation polynomial is an NCE
of degree q = v.
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Appendix B
Theorems
In this section, we give a more precise statement of Pontryagin’s Maximum (Minimum)
Principle.
Theorem B.0.1 (Pontryagin’s Minimum Principle [14]). Let u(t) = [u1(t), . . . , um(t)] be
a piecewise continuous control vector and x(t) = [x1(t), . . . , xn(t)] be an associated contin-
uous and piecewise differentiable state vector defined on the fixed time interval [t0, t1] that
minimizes ∫ t1
t0
f(t,x(t),u(t))dt
subject to the differential equations
xi(t) = gi(t,x(t),u(t)), i = 1, . . . , n,
initial conditions
xi(t0) = xi0, i = 1, . . . , n (xi0 fixed),
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terminal conditions
xi(t1) = xi1, i = 1, . . . , p,
xi(t1) ≥ xit, i = p+ 1, . . . , q (xi1, i = 1, . . . , q fixed),
xi(t1) free, i = q + 1, . . . , n,
and control variable restriction
Xu(t) ∈ U, U a given set in Rm.
We assume that f, g, ∂f/∂xj, and ∂gi/∂xj are continuous functions of all their arguments, for
all i = 1, . . . , n and j = 1, . . . , n. Then there exists a constant λ0 and continuous functions
λ(t) = (λ1(t), . . . , λn(t)), where for all t0 ≤ t ≤ t1 we have (λ0, λ(t)) 6= (0, 0) such that for
every t0 ≤ t ≤ t1
H(t,x∗(t),u(t), λ(t)) ≤ H(t,x∗(t),u∗(t), λ(t)),
where the Hamiltonian function H is defined by
H(t,x,u, λ) = λ0f(t,x,u) +
n∑
i=1
λigi(t,x,u).
Except at points of discontinuity of u∗(t),
λ′(t) = −∂H(t,x∗(t),u∗(t), λ(t))/∂xi, i = 1, . . . , n.
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Finally, the following transversality conditions are satisfied:
λi(t1) no conditions, i = 1, . . . , p,
λi(t1) ≥ 0 (= 0 if x∗i (t1) > xi1)) i = p+ 1, . . . , q,
λi(t1) = 0, i = q + 1, . . . , n.
In addition, the modifications to (B.0.1) generated by the terminal inequalities are given
in Kamien and Schwartz [14], p. 160:
If K(xq(t1), . . . , xn(t1)) ≥ 0 is required, then the transversality conditions
λi(t1) = p ∂K/∂x1, i = q, . . . , n,
p ≤ 0,
pK = 0
are necessary.
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